MX2015005341A - Metodos para controlar la presion arterial y para reducir la disnea durante una insuficiencia cardiaca. - Google Patents
Metodos para controlar la presion arterial y para reducir la disnea durante una insuficiencia cardiaca.Info
- Publication number
- MX2015005341A MX2015005341A MX2015005341A MX2015005341A MX2015005341A MX 2015005341 A MX2015005341 A MX 2015005341A MX 2015005341 A MX2015005341 A MX 2015005341A MX 2015005341 A MX2015005341 A MX 2015005341A MX 2015005341 A MX2015005341 A MX 2015005341A
- Authority
- MX
- Mexico
- Prior art keywords
- blood pressure
- methods
- heart failure
- controlling blood
- dyspnea
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención divulga métodos para controlar, mantener o reducir la presión arterial y/o para tratar, prevenir o aliviar los síntomas tales como disnea, en un paciente que sufre de o es susceptible a una insuficiencia cardiaca aguda. Los métodos involucran la administración de una cantidad efectiva de una composición farmacéutica que comprende un compuesto de dihidropiridina de acción corta, tal como clevidipina. La composición farmacéutica puede administrarse en una dosis inicial, y si la presión arterial no se controla o se mantiene dentro de un rango objetivo de presión arterial o se reduce dentro de un rango objetivo de presión arterial, la dosis inicial puede ajustarse para conseguir una presión arterial dentro del rango objetivo de presión arterial. El paciente puede tener una presión arterial sistólica de aproximadamente 120 mmHg o más.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261719127P | 2012-10-26 | 2012-10-26 | |
| PCT/US2013/066990 WO2014066870A1 (en) | 2012-10-26 | 2013-10-26 | Methods for controlling blood pressure and reducing dyspnea in heart failure |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015005341A true MX2015005341A (es) | 2016-05-24 |
| MX359768B MX359768B (es) | 2018-10-10 |
Family
ID=50545374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015005341A MX359768B (es) | 2012-10-26 | 2013-10-26 | Métodos para controlar la presión arterial y para reducir la disnea durante una insuficiencia cardiaca. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10881645B2 (es) |
| EP (1) | EP2925128B1 (es) |
| JP (2) | JP6329957B2 (es) |
| KR (1) | KR102299073B1 (es) |
| CN (2) | CN110840890A (es) |
| AU (1) | AU2013334081B2 (es) |
| BR (1) | BR112015009291B1 (es) |
| CA (1) | CA2889584C (es) |
| EA (1) | EA030354B1 (es) |
| ES (1) | ES2671639T3 (es) |
| IL (1) | IL238462A0 (es) |
| MX (1) | MX359768B (es) |
| NZ (1) | NZ708511A (es) |
| PL (1) | PL2925128T3 (es) |
| TR (1) | TR201807636T4 (es) |
| UA (1) | UA117571C2 (es) |
| WO (1) | WO2014066870A1 (es) |
| ZA (1) | ZA201503741B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2947486C (en) | 2014-05-19 | 2023-09-26 | The Medicines Company | Clevidipine nanoparticles and pharmaceutical compositions thereof |
| CN112118846B (zh) * | 2019-03-05 | 2024-04-16 | 风树疗法公司 | 治疗急性心力衰竭(ahf)用的含伊司他肟的静脉内制剂 |
| CN114966056B (zh) * | 2022-06-08 | 2024-07-02 | 四川大学华西医院 | 筛查急性主动脉夹层的试剂盒和系统 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9303657D0 (sv) | 1993-11-05 | 1993-11-05 | Astra Ab | Short-acting dihydropyridines |
| SE9303744D0 (sv) | 1993-11-12 | 1993-11-12 | Astra Ab | Pharmaceutical emulsion |
| SE9804002D0 (sv) | 1998-11-23 | 1998-11-23 | Astra Ab | New manufacturing process |
| US9925265B2 (en) * | 2009-11-11 | 2018-03-27 | Chiesi Farmaceutici S.P.A. | Methods of treating or preventing stent thrombosis |
| EA022948B1 (ru) | 2008-05-16 | 2016-03-31 | Кортера, Инк. | Лечение релаксином одышки, ассоциированной с острой сердечной недостаточностью |
| PL2320740T3 (pl) | 2008-08-01 | 2014-09-30 | The Medicines Co | Kompozycje farmaceutyczne klewidypiny oraz sposoby ich wytwarzania z niskim stężeniem zanieczyszczeń |
| WO2010014234A1 (en) | 2008-08-01 | 2010-02-04 | The Medicines Company | Pharmaceutical compositions and methods for stabilizing the same |
| TW201215392A (en) | 2010-06-16 | 2012-04-16 | Gilead Sciences Inc | Use of ranolazine for treating pulmonary hypertension |
| PT2627173E (pt) * | 2010-10-12 | 2015-07-24 | Medicines Co | Formulações de clevidipina em emulsão contendo agentes antimicrobianos |
| CN103781479A (zh) | 2011-04-01 | 2014-05-07 | 医药公司 | 用于减轻中风损害的短效二氢吡啶（氯维地平） |
-
2013
- 2013-10-26 CA CA2889584A patent/CA2889584C/en active Active
- 2013-10-26 KR KR1020157013890A patent/KR102299073B1/ko active IP Right Grant
- 2013-10-26 EA EA201590825A patent/EA030354B1/ru unknown
- 2013-10-26 UA UAA201505170A patent/UA117571C2/uk unknown
- 2013-10-26 AU AU2013334081A patent/AU2013334081B2/en active Active
- 2013-10-26 NZ NZ708511A patent/NZ708511A/en unknown
- 2013-10-26 MX MX2015005341A patent/MX359768B/es active IP Right Grant
- 2013-10-26 PL PL13848937T patent/PL2925128T3/pl unknown
- 2013-10-26 BR BR112015009291-8A patent/BR112015009291B1/pt active IP Right Grant
- 2013-10-26 CN CN201911070111.9A patent/CN110840890A/zh active Pending
- 2013-10-26 JP JP2015539879A patent/JP6329957B2/ja active Active
- 2013-10-26 ES ES13848937.2T patent/ES2671639T3/es active Active
- 2013-10-26 US US14/064,137 patent/US10881645B2/en active Active
- 2013-10-26 CN CN201380068074.2A patent/CN104968199A/zh active Pending
- 2013-10-26 TR TR2018/07636T patent/TR201807636T4/tr unknown
- 2013-10-26 EP EP13848937.2A patent/EP2925128B1/en active Active
- 2013-10-26 WO PCT/US2013/066990 patent/WO2014066870A1/en active Application Filing
-
2015
- 2015-04-26 IL IL238462A patent/IL238462A0/en active IP Right Grant
- 2015-05-26 ZA ZA2015/03741A patent/ZA201503741B/en unknown
-
2018
- 2018-01-31 JP JP2018014665A patent/JP2018065875A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CN104968199A (zh) | 2015-10-07 |
| CN110840890A (zh) | 2020-02-28 |
| UA117571C2 (uk) | 2018-08-27 |
| CA2889584A1 (en) | 2014-05-01 |
| EA201590825A1 (ru) | 2015-09-30 |
| ES2671639T3 (es) | 2018-06-07 |
| EP2925128A4 (en) | 2016-06-08 |
| MX359768B (es) | 2018-10-10 |
| IL238462A0 (en) | 2015-06-30 |
| US20140121247A1 (en) | 2014-05-01 |
| JP2015535258A (ja) | 2015-12-10 |
| WO2014066870A1 (en) | 2014-05-01 |
| JP6329957B2 (ja) | 2018-05-23 |
| AU2013334081A1 (en) | 2015-06-11 |
| JP2018065875A (ja) | 2018-04-26 |
| US10881645B2 (en) | 2021-01-05 |
| KR20150104084A (ko) | 2015-09-14 |
| AU2013334081B2 (en) | 2017-05-18 |
| ZA201503741B (en) | 2022-09-28 |
| BR112015009291B1 (pt) | 2021-03-16 |
| NZ708511A (en) | 2018-11-30 |
| CA2889584C (en) | 2018-08-14 |
| EP2925128B1 (en) | 2018-04-11 |
| EP2925128A1 (en) | 2015-10-07 |
| PL2925128T3 (pl) | 2018-10-31 |
| TR201807636T4 (tr) | 2018-06-21 |
| KR102299073B1 (ko) | 2021-09-09 |
| BR112015009291A2 (pt) | 2017-07-04 |
| EA030354B1 (ru) | 2018-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4233861A3 (en) | Compositions for treatment of essential tremor | |
| MX2023012450A (es) | Esketamina para el tratamiento de la depresion. | |
| MX2022004012A (es) | Solucion de bloqueo de cateter y terapia de bloqueo de cateter. | |
| MX362626B (es) | Métodos para tratar pacientes pediátricos usando dexmedetomidina.. | |
| NZ714963A (en) | Compositions and methods for treating anemia | |
| TN2011000217A1 (en) | Pirfenidone treatment for patients with atypical liver fuction | |
| PH12016501357A1 (en) | Pharmaceutical preparation containing pyridylamino acetic acid compound | |
| JP2017501154A5 (es) | ||
| UA105191C2 (ru) | Лечение пирфенидоном пациентов с атипической функцией печени | |
| RU2015134581A (ru) | Доноры нитроксила с улучшенным терапевтическим индексом | |
| JP2015532293A5 (ja) | 糖尿病患者における心不全の治療用組成物 | |
| NZ754328A (en) | Marker for acid sphingomyelinase disorders and uses thereof | |
| WO2012042197A3 (en) | Low dose pharmaceutical composition comprising zanamivir | |
| NZ708511A (en) | Methods for controlling blood pressure and reducing dyspnea in heart failure | |
| NZ751972A (en) | Treatment of prurigo nodularis | |
| WO2010107251A3 (ko) | 파카스트리사민을 유효성분으로 함유하는 과증식성 피부질환과 악성흑생종의 예방 또는 치료용 약학적 조성물 | |
| MY179794A (en) | Compound composition for inhalation used for treating asthma | |
| RU2011123367A (ru) | Способ лечения или профилактики тромбоза с использованием этексилата дабигатрана или его соли с улучшенной эффективностью по сравнению со стандартным лечением варфарином | |
| MX2020007222A (es) | Metodos para el tratamiento de afecciones inflamatorias de la piel. | |
| PH12015502465A1 (en) | Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias | |
| EA201690903A1 (ru) | Лечение глаукомы с использованием лаквинимода | |
| WO2013058627A3 (ko) | 레바미피드를 유효성분으로 포함하는 비만의 예방 또는 치료용 조성물 | |
| PH12016500716B1 (en) | Pharmaceutical dosage forms containing sodium-1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1h-1,2,3-triazol-1-yl)-1h-pyrazol-5-olate | |
| Morales | Bradycardia and hypotension: case report | |
| NZ600486A (en) | Pirfenidone treatment for patients with atypical liver function |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: CHIESI FARMACEUTICI S.P.A. |
|
| FG | Grant or registration |